- Home
- CUB vs NGNE Comparison
CUB vs NGNE Comparison
Compare CUB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUB
- NGNE
- Stock Information
- Founded
- CUB 2024
- NGNE 2003
- Country
- CUB United States
- NGNE United States
- Employees
- CUB N/A
- NGNE N/A
- Industry
- CUB
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- CUB
- NGNE Health Care
- Exchange
- CUB NYSE
- NGNE Nasdaq
- Market Cap
- CUB 321.1M
- NGNE 325.3M
- IPO Year
- CUB 2024
- NGNE N/A
- Fundamental
- Price
- CUB $10.47
- NGNE $21.87
- Analyst Decision
- CUB
- NGNE Strong Buy
- Analyst Count
- CUB 0
- NGNE 7
- Target Price
- CUB N/A
- NGNE $41.86
- AVG Volume (30 Days)
- CUB 14.0K
- NGNE 134.0K
- Earning Date
- CUB 08-22-2025
- NGNE 08-12-2025
- Dividend Yield
- CUB N/A
- NGNE N/A
- EPS Growth
- CUB N/A
- NGNE N/A
- EPS
- CUB 0.34
- NGNE N/A
- Revenue
- CUB N/A
- NGNE $925,000.00
- Revenue This Year
- CUB N/A
- NGNE N/A
- Revenue Next Year
- CUB N/A
- NGNE N/A
- P/E Ratio
- CUB $31.19
- NGNE N/A
- Revenue Growth
- CUB N/A
- NGNE N/A
- 52 Week Low
- CUB $9.96
- NGNE $6.88
- 52 Week High
- CUB $10.61
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- CUB N/A
- NGNE 54.92
- Support Level
- CUB N/A
- NGNE $20.72
- Resistance Level
- CUB N/A
- NGNE $23.88
- Average True Range (ATR)
- CUB 0.00
- NGNE 1.59
- MACD
- CUB 0.00
- NGNE -0.15
- Stochastic Oscillator
- CUB 0.00
- NGNE 48.51
About CUB LIONHEART HOLDINGS
Lionheart Holdings is a blank check company.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.